Tumor-associated macrophages are associated with response to neoadjuvant chemotherapy and poor outcomes in patients with triple-negative breast cancer

• Published in: Journal of Cancer Vol. 12; no. 10; pp. 2886 - 2892
• Main Authors: Ye, Jia-Hui, Wang, Xiao-Hua, Shi, Jia-Jun, Yin, Xi, Chen, Cheng, Chen, Yan, Wu, Hong-Yan, Jiong, Shi, Sun, Qi, Zhang, Meng, Shi, Xian-Biao, Zhou, Guo-Ren, Hassan, Shahzeb, Feng, Ji-Feng, Xu, Xin-Yun, Zhang, Wei-Jie
• Format: Journal Article
• Language: English
• Published: Australia Ivyspring International Publisher Pty Ltd 01.01.2021; Ivyspring International Publisher
• Subjects: Biopsy; Breast cancer; Cancer therapies; Chemotherapy; Ethics; Histology; Lumpectomy; Lymphatic system; Mastectomy; Medical prognosis; Menstruation; Metastasis; Patients; Radiation therapy; Research Paper; Statistical analysis; Surgery; Tumors; neoadjuvant chemotherapy; triple-negative breast cancer; prognosis; tumor-associated macrophages
• ISSN: 1837-9664; 1837-9664
• DOI: 10.7150/jca.47566

Tumor-associated macrophages (TAMs) play an essential role in tumor progression and metastasis. However, the role of TAMs in neoadjuvant chemotherapy (NAC) is unclear and need to be identified. The main subject of this study was to investigate whether TAMs are related to the chemotherapeutic response with triple-negative breast cancers (TNBC). We retrospectively analyzed pretreatment tissue from patients who received NAC and followed by a mastectomy or breast-conservation for stage II-III TNBC in this study. The association between TAMs and the pathological complete response (pCR) rate of TNBC to NAC was analyzed. In addition, the correlation of the TAMs with recurrence-free survival (RFS) in patients with TNBC was also evaluated. Of the 91 patients, 31 (34.1%) patients experienced pathological complete response (pCR) after completion of NAC. Regarding the chemotheraptic response, patients with low infiltration of CD163 macrophages achieved a significantly higher rate of pCR. Importantly, Kaplan-Meier survival shown that patients with high infiltration of CD163 macrophages and non-pCR had poor OS and RFS. our data showed that TAMs may predict chemotherapeutic response and can be used as a promising prognostic candidate for poor survival in TNBC patients treated with NAC.